Pinpointing who will and won’t get Alzheimer’s disease is tricky for doctors, but new research suggests it may soon get ...

USC researchers have found a promising new brain scan marker that could better detect Alzheimer’s risk — but only for some.

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Researchers at the Keck School of Medicine developed a tau PET imaging cut-point to identify early Alzheimer’s signs. The cut ...

A team of researchers from the Keck School of Medicine of USC's Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI) has identified a new brain imaging benchmark that may improve ...

The team used a special type of brain scan called tau PET, which tracks a protein known as tau that builds up in the brain ...

Vizamyl is now additionally indicated for use in a selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information.

US FDA approves expanded label for GE HealthCare’s Vizamyl PET imaging agent for beta amyloid detection: Arlington Heights, Illinois Thursday, June 26, 2025, 13:00 Hrs [IST] GE ...

The FDA expanded the uses of GE HealthCare’s Vizamyl imaging agent for highlighting the presence of beta amyloid proteins in the brain, with new green lights that enable more objective sc | The ...

It’s a groundbreaking step forward, but these scans are also showing that the disease develops differently in Black patients.